Q-omics provides the consensus-scored TRMT9B profile across patient tissues and cancer cell-line models. TRMT9B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRMT9B is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TRMT9B RNA expression shows 17,803 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where TRMT9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT9B survival associations across molecular data types. TRMT9B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT9B RNA expression–survival associations across cancer types. High TRMT9B expression shows unfavorable associations in LGG, but favorable associations in KIRP, HNSC, COAD, KIRC and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRMT9B RNA expression.
This table summarizes TRMT9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRMT9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT9B shows lower tumor expression in HNSC, THCA, LUSC, LUAD, KIRC and BRCA. The HNSC box plot shows higher TRMT9B RNA expression in normal versus tumor tissue (log2 FC = −0.620, t-test p < 0.001).
This table shows molecular features associated with TRMT9B in patient tissues and cancer cell lines. In patient samples, TRMT9B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT9B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
